Crane Co. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Crane Co. on July 23, 2018. The filing primarily serves to announce the Company's results of operations for the quarter ended June 30, 2018, and to provide detailed updates regarding asbestos liability claims and costs. The financial data supplement referenced in the filing is furnished as Exhibit 99.1.
Key Financial Metrics: Asbestos Liability and Costs
The filing provides specific data regarding asbestos-related costs, which are distinct from the Company's core operating results. The following metrics are reported for the periods ended June 30, 2018:
- Total Asbestos Costs Incurred (Six Months): $55.9 million (compared to $44.8 million in the prior year period).
- Settlement/Indemnity Costs Incurred (Six Months): $42.0 million.
- Defense Costs Incurred (Six Months): $13.9 million.
- Pre-tax Cash Payments (Six Months): $34.9 million (net of insurance receipts).
- Total Asbestos Liability Recorded: $559 million as of June 30, 2018 (down from $696 million as of December 31, 2016).
- Current Portion of Liability: $85 million (estimated costs expected to be paid within the next 12 months).
- Insurance Receivable Asset: $104 million as of June 30, 2018.
- Pending Claims: 29,920 claims as of June 30, 2018.
Material Changes and Activity
Asbestos activity showed an increase in costs incurred compared to the prior year. Settlement and indemnity costs incurred for the six months ended June 30, 2018, were $42.0 million, a significant increase from $25.8 million in the same period in 2017. This increase was driven by specific settlements and indemnity amounts recognized in the second quarter of 2018, including resolutions of the James Nelson, James Poage, and George Coulbourn claims.
While the total liability recorded in 2016 was $696 million, the liability decreased to $559 million by June 30, 2018, primarily due to cash payments made for settled claims and defense costs. The number of pending claims decreased from 30,990 at the beginning of the quarter to 29,920 at the end of the quarter, driven by 1,358 dismissals and 332 settlements, offset by 620 new claims.
Outlook, Risks, and Contingencies
Liability Estimate Methodology: The Company utilizes an independent actuarial firm to estimate asbestos liability through 2059. Management determined that no change to the liability estimate was warranted for the period ended June 30, 2018, as actual experience approximated assumptions.
Key Risks and Uncertainties:
- Estimation Uncertainty: The ultimate exposure is subject to significant uncertainties regarding the timing, severity, and quantity of future claims. Factors include the number of new mesothelioma claims, average settlement costs, dismissal rates, and defense costs.
- Legal Developments: Changes in case law, legislative solutions, or substantial adverse verdicts could materially alter the estimated liability.
- Insurance Recovery: The Company estimates that approximately 21% of the liability will be reimbursed by insurers. However, actual reimbursements vary based on insurer financial viability, policy terms, and coverage gaps.
- Pending Litigation: The Company is awaiting a decision from the Supreme Court of Florida in the Richard DeLisle claim, which could impact future liability estimates.
Guidance: The filing does not provide specific forward-looking financial guidance for revenue or earnings, as the detailed quarterly results are contained in the separate press release (Exhibit 99.1). The Company notes that cash payments for asbestos liabilities are expected to continue for years past 2059.
Investor Verification Checklist
- Verify the specific revenue, profit, and cash flow figures for the quarter ended June 30, 2018, in the attached Exhibit 99.1 (Earnings Press Release), as this 8-K does not contain those core operating numbers.
- Monitor the outcome of the Richard DeLisle claim pending before the Supreme Court of Florida, as a reversal could impact future liability estimates.
- Review the trend of new mesothelioma claims versus dismissals to assess the stability of the $559 million liability reserve.
- Track the actual insurance reimbursement rates against the estimated 21% recovery rate to evaluate the net cost impact.
- Confirm the status of the single remaining solvent excess insurer that has not entered into a coverage-in-place agreement.